Chicago Cancer Institutions Collaborate to Improve Care
November 8th 2017Over the last four years, the Coleman Supportive Oncology Collaborative (CSOC), a group of professionals from academic, community and public cancer centers and hospice providers, has been developinging tools and resources to address gaps in cancer care in the Chicago area.
Significant Rate of Febrile Neutropenia Seen in CDK 4/6 Inhibitor Based Regimens
November 6th 2017Cyclin D–dependent kinase (CDK) 4/6 inhibitors have proven to be effective treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer. But, much like many cancer therapies, there are challenges when it comes to toxicity.
Many Tanning Salons Not Compliant With State Laws, Study Finds
November 3rd 2017Overall, 159 of the 427 tanning salons were out of compliance, and most of them were in rural locations and southern regions of the United States. Additionally, this was more common in independently owned salons, in states with younger age groups being regulated and in states with more than one tanning regulation.
Expert Discusses the Present and Future of Genetic Testing in Breast Cancer
November 2nd 2017Laura J. van’t Veer, PhD, discussed determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.
Acalabrutinib Granted FDA Approval for Mantle Cell Lymphoma Treatment
October 31st 2017The FDA has granted an accelerated approval to acalabrutinib (Calquence) as a treatment for adult patients with mantle cell lymphoma (MCL) following at least 1 prior therapy, based on objective response rates (ORR) in a single-arm trial.
IV Rolapitant Approved for Delayed CINV Treatment
October 26th 2017The FDA has approved intravenous (IV) rolapitant (Varubi) for use in combination with other antiemetic agents to treat delayed chemotherapy-induced nausea and vomiting (CINV) in adults, according to TESARO, the manufacturer of the agent.
Dabrafenib Plus Trametinib Granted Breakthrough Therapy Designation for Melanoma
October 24th 2017The FDA has awarded the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) a breakthrough therapy designation for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection.
Best Practices to Reduce Cancer Disparities Among LGBTI Populations
October 5th 2017In April 2017, the American Society of Clinical Oncology released a position statement, Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations, with the goal of educating healthcare providers about challenges faced by LGBTI individuals with cancer.
Death Rates Dropping, But Racial Disparities Remain in Breast Cancer
October 4th 2017Improved treatment and early detection mean fewer women in the United States are dying from breast cancer, according to a study released by the American Cancer Society (ACS) that examined trends in the disease.
Abemaciclib Approved for HR+/HER2- Breast Cancer
September 28th 2017The FDA approved abemaciclib (Verzenio) for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy. The CDK4/6 inhibitor has also been approved as a monotherapy for patients with HR+/HER2- breast cancer with metastatic disease who have previously received endocrine therapy and chemotherapy.